Despite losing a $10 billion bid for Metsera to Pfizer, Novo Nordisk's CEO Mike Doustdar remains determined to pursue new opportunities in the obesity and diabetes sectors. The company aims to reclaim its position in the booming weight-loss market.
In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
Two biotech companies are developing groundbreaking gene therapies that could lead to a single injection for weight loss and blood sugar control. Initial tests show promising results in mice, with human trials on the horizon.
Discover the surprising benefits of aligning your daily habits with your body's circadian rhythms! Learn how the time you sleep, eat, and exercise can significantly impact your health and prevent chronic diseases.
As demand for weight loss and diabetes drugs surges, Eli Lilly and Novo Nordisk dominate the market. Discover the challenges, competition, and future of this booming industry.
Eli Lilly's stock surged 3.9% after an outstanding Q3 earnings report, surpassing analysts' expectations with $7.02 per share and $17.6 billion in sales. The company raised its yearly guidance, signaling strong growth potential.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.
A new report reveals that the U.S. adult obesity rate has declined to 37% in 2025, down from a record 39.9% in 2022, as more Americans turn to weight loss drugs like GLP-1 injectables. With 7.6 million fewer obese adults, is this the start of a healthier trend?
A recent survey reveals that almost 90% of U.S. adults are unaware of cardiovascular-kidney-metabolic syndrome, despite being at high risk. Learn about the interconnected risks and how to prevent this emerging health crisis.
A groundbreaking new classification, Type 5 diabetes, is emerging from decades of overlooked cases. Researchers urge formal recognition to improve treatment and understanding of this malnutrition-linked condition affecting millions.